A liquid biopsy is a blood test that detects fragments of cancer, or other disease signals, circulating in your bloodstream. Instead of surgically removing a piece of tumor tissue, a doctor draws a standard blood sample and sends it to a lab, where specialists analyze the plasma for tiny biological clues shed by tumors. Results typically come back within two to three weeks.
The concept is simple: tumors don’t stay perfectly contained. They constantly release material into the blood, including bits of their DNA, whole tumor cells that have broken free, and small packages of proteins and genetic material. A liquid biopsy captures and analyzes these materials to reveal what’s happening inside a tumor without ever touching it.
What a Liquid Biopsy Detects
The blood sample is separated into its solid and liquid components. A pathologist then examines the plasma (the liquid portion) for several types of tumor-derived material.
The most commonly analyzed is circulating tumor DNA, or ctDNA. When tumor cells die, they break apart and release fragments of their DNA into the bloodstream. These fragments carry the same genetic mutations found in the tumor itself, so sequencing them can reveal what’s driving the cancer at a molecular level. The amount of ctDNA in your blood also tracks with tumor size, which makes it useful for monitoring whether a treatment is working.
Labs can also look for circulating tumor cells (CTCs), which are intact cancer cells that have separated from the primary tumor and entered the bloodstream. CTC counts are used in breast cancer to help estimate prognosis and have been incorporated into clinical guidelines in multiple countries. Beyond ctDNA and CTCs, researchers analyze exosomes, tiny membrane-bound packages that cells use to communicate. Tumor-derived exosomes carry proteins, RNA, and other molecules that reflect the biology of the cancer they came from.
How It Compares to a Traditional Biopsy
A traditional tissue biopsy requires a needle insertion or a surgical procedure to physically remove a piece of the tumor. That’s invasive, sometimes painful, and occasionally risky depending on where the tumor is located. Some tumors sit in places that are difficult or dangerous to reach with a needle, like deep in the lungs or brain. In those cases, getting a tissue sample may not be feasible at all.
A liquid biopsy, by contrast, requires only a standard blood draw. In a head-to-head comparison in metastatic non-small cell lung cancer, liquid biopsy results came back an average of 26.8 days faster than tissue biopsy results. For the key genetic markers that guide treatment decisions, the two methods agreed 94.8% to 100% of the time. A liquid-first approach successfully identified those markers in 76.5% of patients, compared to 54.9% with a tissue-first approach. Survival outcomes were the same regardless of which method guided treatment.
Liquid biopsies also have a structural advantage: they can capture genetic diversity across the entire tumor and even across multiple tumor sites, since all of them shed DNA into the blood. A tissue biopsy only samples one small area, which may not represent the full picture if the tumor has evolved differently in different spots. The tradeoff is that ctDNA levels can be very low, especially in early-stage cancers or small tumors, which can make detection harder.
Clinical Uses in Cancer Care
Liquid biopsies serve several distinct roles, and their value changes depending on where someone is in their cancer journey.
Guiding treatment decisions. By identifying the specific genetic mutations driving a cancer, liquid biopsy helps oncologists match patients to targeted therapies designed for their molecular profile. This is already a routine part of care in non-small cell lung cancer, where several FDA-cleared plasma-based tests can detect mutations that determine which drugs are most likely to work. The European Medicines Agency authorized blood-based testing for one of these key mutations (EGFR) back in 2014.
Monitoring treatment response. Because ctDNA levels rise and fall with tumor activity, repeated blood draws over time can show whether a treatment is shrinking the cancer or whether the tumor is developing resistance. This has been demonstrated in lung cancer, bone cancer, and nasopharyngeal cancer, among others. Rather than waiting weeks for a follow-up scan, doctors can track molecular changes in real time.
Detecting recurrence early. After surgery or initial treatment, some patients have microscopic cancer cells that persist below the threshold of what imaging can see. This is called minimal residual disease. Liquid biopsy can pick up these trace signals. In colorectal and gastric cancer, ctDNA-based monitoring has detected recurrence an average of 10 months earlier than conventional methods like CT scans or blood protein markers. That lead time can open a window for earlier intervention.
Early cancer detection. Liquid biopsy has also been applied to early detection of lung and breast cancer, though this remains a more challenging application. Early-stage tumors shed less DNA, making the signal harder to distinguish from background noise.
FDA-Approved Tests
Several liquid biopsy tests have been cleared or approved by the FDA as companion diagnostics, meaning they’re tied to specific treatment decisions. The most prominent include FoundationOne Liquid CDx, a broad plasma-based test approved for identifying treatable mutations in non-small cell lung cancer, and the cobas EGFR Mutation Test v2, which can be run on either tissue or plasma to detect specific mutations that respond to targeted lung cancer drugs. Blood-based tests also exist for BRCA mutations in breast and ovarian cancer, and for mutations relevant to acute myeloid leukemia.
These approved tests are used alongside, or sometimes instead of, tissue biopsy. In cases where a tissue sample can’t be obtained, liquid biopsy may be the only option for molecular profiling.
Uses Beyond Cancer
While cancer dominates the conversation around liquid biopsy, the same principle applies to other conditions. Damaged or stressed cells throughout the body release DNA and other molecules into the bloodstream, not just tumor cells.
In cardiology, circulating DNA and small RNA molecules in plasma have shown promise as markers for heart attacks, heart failure, and stroke. After a heart transplant, rising levels of donor-derived DNA in the recipient’s blood can signal organ rejection before symptoms appear. Liquid biopsy techniques are also used in prenatal testing, where fragments of fetal DNA circulating in the mother’s blood can screen for chromosomal conditions like Down syndrome without an invasive procedure like amniocentesis. Applications in infectious disease and neurology are also being explored.
What the Experience Is Like
From a patient’s perspective, a liquid biopsy feels identical to any routine blood draw. A healthcare provider takes a blood sample from your arm, labels it, and sends it to a specialized lab. There’s no sedation, no recovery time, and no wound care. You can go about your day immediately afterward. Results typically take two to three weeks, depending on the complexity of the analysis.
Because the test is so simple to perform, it can be repeated as often as needed. This is one of its biggest practical advantages over tissue biopsy: tracking changes over time doesn’t require repeated invasive procedures. For someone undergoing cancer treatment, that can mean better monitoring with significantly less physical burden.